Stockreport
Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) [Seeking Alpha]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
The HIV franchise remains GILD's core strength, while Trodelvy's first-line approval in mTNBC supports growth. Cell therapy headwinds and GILD reliance on M&A for pipeline diversification introduce execution and strategic risks. Scenario and Monte Carlo analyses suggest a realistic GILD trading range of $98–$209/share, with upside tied to clinical wins. Stanislaw Pytel/DigitalVision via Getty Images Gilead Overview Gilead Sciences, Inc. ( GILD ) has been a beneficiary of a big pharma rally these past few months. Although I cannot so much speak for the others, I feel confident that Gilead's stock appreciation This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. Financial models presented here, including DCF, rNPV, and scenario analyses, are illustrative tools based on the
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? [Yahoo! Finance][Yahoo! Finance]
- Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline [Yahoo! Finance][Yahoo! Finance]
- Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal [Yahoo! Finance][Yahoo! Finance]
- Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal [Yahoo! Finance][Yahoo! Finance]
- Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 3/27/26 - Form 144
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form ARS
- GILD's page on the SEC website
- More